Our Portfolio Biopharmaceuticals Biopharmaceuticals All Companies Opportunities-II Abcuro Treatment for Autoimmune Disorders and Rare Cancers Newton, MA NLV-IV / Opportunities-II Electra Therapeutics SIRP-directed therapeutics for immunological diseases and cancer. South San Francisco, CA NLV-III/Opportunities I Cogent Biosciences Therapies for systemic mastocytosis and gastrointestinal stromal tumors (GIST) Cambridge NASDAQ: COGT Opportunities-II Dice Therapeutics Acquired by Lilly Immunology for patients with debilitating diseases South San Francisco, CA NASDAQ: DICE NLV-IV Saniona Development of therapies for rare eating disorders Denmark OMX: SANION NLV-IV Escape Bio Development of therapies for genetic neurodegenerative diseases South San Francisco, CA NLV-IV / Opportunities-II Star Therapeutics Antibody therapeutics for rare diseases South San Francisco, CA OPPORTUNITIES-II Edgewise Therapeutics Novel, transformative therapies for serious muscle diseases Boulder, CO NASDAQ: EWTX BPO-II Rocket Pharma Developing transformative gene therapy-based treatments for cardiovascular disease Philadelphia, PA NASDAQ: RCKT NLV-IV, NLV-III Qlaris Bio Novel treatments for ocular diseases Boston, MA NLV-IV/OPPORTUNITIES-II CuraSen Therapeutics, Inc. Development of drugs for the treatment of CNS and neurodegenerative diseases San Carolos, CA NLV-IV / OPPORTUNITIES-I Sierra Oncology Treatment for Myelofibrosis Cancer San Mateo, CA NLV-IV / OPPORTUNITIES-II ReViral Clinical stage biopharmaceutical company focused on the development of antivirals for the treatment of (Respiratory Syncytial Virus ) RSV Hertfordshire, United Kingdom NLV–III/Opportunities-II Arvinas Platform for small-molecule drugs that induce targeted degradation of disease-causing intracellular proteins New Haven, CT NASDAQ: ARVN NLV-III / OPPORTUNITIES-I Aptinyx Novel NMDA modulator small molecule platform company for challenging neurological disorders. Evanston, IL NASDAQ: APTX NLV-III / OPPORTUNITIES-I Braeburn Pharmaceuticals Long-acting therapies for opioid use disorders. Princeton, NJ NLV–III / OPPORTUNITIES-I Deciphera Proprietary platform of novel kinase inhibitors for the treatment of cancer. Lead programs altiratinib (targeting MET) and DCC-2618 (targeting KIT) are clinical stage. Waltham, MA NASDAQ: DCPH NLV–III / OPPORTUNITIES-I Dimension Therapeutics Liver-focused gene therapy platform addressing genetic diseases with high need, including hemophilia and orphan metabolic diseases. Cambridge, MA NASDAQ: DMTX NLV–III / OPPORTUNITIES-I PDS Biotechnology Clinical-stage immunotherapies to treat various early-stage and late-stage cancers Berkeley Heights, NJ NASDAQ: PDSB NLV-III / OPPORTUNITIES-II Iterum Therapeutics Novel antibiotic drug development Ireland / Chicago, IL NASDAQ: ITRM
Opportunities-II Abcuro Treatment for Autoimmune Disorders and Rare Cancers Newton, MA NLV-IV / Opportunities-II Electra Therapeutics SIRP-directed therapeutics for immunological diseases and cancer. South San Francisco, CA NLV-III/Opportunities I Cogent Biosciences Therapies for systemic mastocytosis and gastrointestinal stromal tumors (GIST) Cambridge NASDAQ: COGT Opportunities-II Dice Therapeutics Acquired by Lilly Immunology for patients with debilitating diseases South San Francisco, CA NASDAQ: DICE NLV-IV Saniona Development of therapies for rare eating disorders Denmark OMX: SANION NLV-IV Escape Bio Development of therapies for genetic neurodegenerative diseases South San Francisco, CA NLV-IV / Opportunities-II Star Therapeutics Antibody therapeutics for rare diseases South San Francisco, CA OPPORTUNITIES-II Edgewise Therapeutics Novel, transformative therapies for serious muscle diseases Boulder, CO NASDAQ: EWTX BPO-II Rocket Pharma Developing transformative gene therapy-based treatments for cardiovascular disease Philadelphia, PA NASDAQ: RCKT NLV-IV, NLV-III Qlaris Bio Novel treatments for ocular diseases Boston, MA NLV-IV/OPPORTUNITIES-II CuraSen Therapeutics, Inc. Development of drugs for the treatment of CNS and neurodegenerative diseases San Carolos, CA NLV-IV / OPPORTUNITIES-I Sierra Oncology Treatment for Myelofibrosis Cancer San Mateo, CA NLV-IV / OPPORTUNITIES-II ReViral Clinical stage biopharmaceutical company focused on the development of antivirals for the treatment of (Respiratory Syncytial Virus ) RSV Hertfordshire, United Kingdom NLV–III/Opportunities-II Arvinas Platform for small-molecule drugs that induce targeted degradation of disease-causing intracellular proteins New Haven, CT NASDAQ: ARVN NLV-III / OPPORTUNITIES-I Aptinyx Novel NMDA modulator small molecule platform company for challenging neurological disorders. Evanston, IL NASDAQ: APTX NLV-III / OPPORTUNITIES-I Braeburn Pharmaceuticals Long-acting therapies for opioid use disorders. Princeton, NJ NLV–III / OPPORTUNITIES-I Deciphera Proprietary platform of novel kinase inhibitors for the treatment of cancer. Lead programs altiratinib (targeting MET) and DCC-2618 (targeting KIT) are clinical stage. Waltham, MA NASDAQ: DCPH NLV–III / OPPORTUNITIES-I Dimension Therapeutics Liver-focused gene therapy platform addressing genetic diseases with high need, including hemophilia and orphan metabolic diseases. Cambridge, MA NASDAQ: DMTX NLV–III / OPPORTUNITIES-I PDS Biotechnology Clinical-stage immunotherapies to treat various early-stage and late-stage cancers Berkeley Heights, NJ NASDAQ: PDSB NLV-III / OPPORTUNITIES-II Iterum Therapeutics Novel antibiotic drug development Ireland / Chicago, IL NASDAQ: ITRM
